Tiny study probes why MS drug may miss hidden immune cells

NCT ID NCT06495593

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will examine lymph nodes from 5 people with relapsing-remitting multiple sclerosis who are starting ocrelizumab treatment. The goal is to see how effectively the drug removes B cells from lymph nodes, since these cells are known to be important in MS but are not well studied in lymphoid tissue. The findings may help explain why some patients continue to have disease activity despite treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ocrelizumab
What this could lead to: If successful, this could help explain why some MS patients still have disease activity despite ocrelizumab treatment, potentially guiding future therapies.
What could go wrong: This is a very small study (5 participants) and only observes immune cells in lymph nodes. It does not test a new treatment or directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

University of California, San Francisco

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.